Dallas, Texas 11/04/2013 (Financialstrend) – In Friday’s trading, Celgene Corporation (NASDAQ:CELG) rose by 1.90%. The opening price of the shares was $149.27, which climbed to an intraday high of $151.45 and dipped to a close of $151.30. Approximately 2.37 million shares were traded on Friday while an average volume of 2.85 million shares were traded over a 30 day period. The 52-week low of Celgene Corporation (NASDAQ:CELG) shares is $71.23 and its 52-week high is $161.64. The company has a market capitalization of $62.35 billion.
About the company
Celgene Corporation (NASDAQ:CELG) is a global biopharma company. It is primarily involved in discovering, developing and commercializing therapies that are designed to treat cancer & immune-inflammatory-related diseases. Celgene Corporation (NASDAQ:CELG) is involved in the research & development, which is specifically designed to bring ne- therapies to market. The company is also engaged in research for several scientific areas that might deliver therapies and also focus in areas, like intracellular signaling-pathways in cancer & immune cells, immune-modulation in cancer & autoimmune diseases, & therapeutic application of cell-therapies.
The company’s products
Celgene Corporation (NASDAQ:CELG)’s main commercial-stage products include VIDAZA, REVLIMID, ABRAXANE, THALOMID and ISTODAX. Its Additional sources of revenue cover a licensing-agreement with Novartis- this entitles it to various royalties on FOCALIN XR & the entire RITALIN-family of drugs, sale of services via its Cellular Therapeutics subsidiary & other miscellaneous0licensing agreements. In 2012 March it acquired Avila Therapeutics.
Celgene Corporation (NASDAQ:CELG), invests in research &development, & the drug candidates in the company’s pipeline at different stages of preclinical & clinical development. These candidates are pomalidomide & apremilast, its oral anti-cancer & anti-inflammatory agents. Also, PDA-001- the its cellular therapy, oral azacitidine- CC-223 & CC-115 for hematological & solid tumor malignancies, CC-122, the company’s anti-cancer pleiotropic-pathway modifier, and ACE-011 & ACE-536 biological-products used in anemia in several clinical-settings of unmet need.